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Summary 
 
Pervasive computing brings together information and communications technology (ICT) through a wide 
variety of computing devices. Although most medical devices are not computing devices per se, a growing 
number of these are coming to rely on ICT whether by means of logging and telemetry functions (e.g. 
portable or home healthcare devices) or through their deployment in networked hospital environments. 
Furthermore, with the trend towards electronic patient records, it is likely that data from all manner of 
medical equipment will be transmitted through healthcare ICT systems. As a result of this convergence of 
technologies, pervasive healthcare design engineers need to have a good understanding of the regulatory 
environment in which medical device development and deployment is placed, and awareness of the 
evidence-based and cost-sensitive processes of healthcare technology assessment. This is on top of 
adherence to the increasingly sector-specific engineering methods and standards that guide electrical and 
computing equipment product designers in order to ensure safety-critical quality devices and systems. 
This chapter aims to introduce the routes and requirements for realizing medical devices, enabling the 
pervasive healthcare engineer to enter the minds of the regulators and assessors and to better 
understand the industrial processes. In the first section the concept of Health Technology Assessment is 
introduced, the framework that judges the effectiveness and value of a device. The second section 
presents the regulations pertaining to medical devices in some detail including definitions and 
classifications, standards and quality systems, and the key aspects of conformity processes in Europe and 
North America. Some newly proposed concepts in clinical trials are outlined which may, if adopted, be 
particularly suited to medical devices. Also covered in this section are deployment and data issues, the 
former to ensure continued monitoring of the device and the latter arising from the link between the 
predominately independent worlds of devices and computer networks that are now coming together in 
pervasive healthcare. The third section examines the product design process for medical devices that is 
being developed by the Multidisciplinary Assessment of Technology Centre for Healthcare (MATCH) 
research programme. The concluding section reiterates the multidisciplinary environment of the 
pervasive healthcare innovator, and points to sources of information and advice. 
1. Health technology assessment  
 
1.1 The evidence-based environment 
 
Design engineers should already be intimately familiar with the concepts of product lifecycle, quality 
control standards and regulations, and increasingly with the need to take a user-centered approach. For 
successful healthcare technology development, however, we must include two additional concepts: firstly 
evidence-based practice, which began in clinical medicine but is now commonplace across healthcare 
including areas such as information management and device or facility design, and secondly an 
understanding of reimbursement processes for healthcare technologies. For the purposes of this chapter 
these two concepts are tied together into the process known as Health Technology Assessment (HTA).  
Evidence-based practice is described by Booth as follows:
1
  
‘Evidence-based medicine (EBM) is “the conscientious, explicit, and judicious use of current best evidence 
in making decisions about the care of individual patients. The practice of evidence based medicine means 
integrating individual clinical expertise with the best available external clinical evidence from systematic 
research” (Sackett et al., 1996). Evidence-based practice is, by implication, the systematic application of 
rigorous scientific methods to the evaluation of the effectiveness of health care interventions. This can be 
broadened to include such considerations as appropriateness, clinical decision-making, economic 
evaluation, health technology assessment, outcomes measurement and risk management.’
 
The entrance of evidence-based practice in the context of healthcare technologies means not only that a 
new design should show efficacy in relation to risk for a specific therapeutic procedure by the gathering of 
appropriate clinical evidence (which may be mandatory, depending on the device class), but that it must 
prove its clinical effectiveness with respect to existing alternatives in terms of both efficacy and cost, and 
according to the healthcare allocation policy of the payer (e.g. equitable provision, or otherwise, of a 
treatment). Therefore evidence-based practice as related to healthcare technologies can be regarded to a 
great extent as the antithesis of the technology-push mentality found in the marketing of consumer 
electronics.  
The implication for design engineers is that knowledge of its future assessment should feed into the 
development process of a device or system at as early a stage as possible, so that the appropriate design 
choices are made. As Baxter shows, early investment in the front-end of the design process is an 
important general principle for producing any successful new product, such that 85%-90% of its overall 
costs will have already been committed by decisions made before detailed design or production 
engineering begins.
2
 This figure may be even greater for medical devices because modifying a design at a 
late stage means retracing expensive and time-consuming regulatory processes. 
 
 
 
1.2 Reimbursement issues 
 
Most medical technology products are quite different from consumer products since very few are 
available over-the-counter, and patients do not often pay the full cost of a device-related medical 
procedure or diagnostic test themselves. Instead, a medical device manufacturer will seek reimbursement 
from the patient’s healthcare provider, who may be a public institution like a national health service or a 
private body such as a private clinic or health insurer. Reimbursement mechanisms vary greatly between 
different countries (and even between regions within some countries) and are quite complex in terms of 
the different mixes of public and private systems and product types covered. Access to specific healthcare 
products, especially in private care regimes, may also depend on patient factors such as age, income and 
employment status. From the technology manufacturer’s point of view, this presents an unhelpfully 
fragmented and non-harmonized environment to market their products in. 
As highlighted in a comprehensive Clinica report on reimbursement by Bromley et al., devices are being 
heavily implicated as a major cost driver for healthcare, and clinical evidence is increasingly being called 
for by the payers to justify these costs, whether it is for large capital items used for diagnostics or 
personal devices.
3
 Papatheofanis outlines five economic variables that payers typically use for health 
economic analysis: cost of therapy, cost of side-effects, costs avoided as a result of treatment, costs 
utilized based on information from diagnostics or referral of a patient, and costs utilized or saved during 
extended years of life as a result of therapy.
4
 For the design engineer, this necessitates some 
understanding of both treatment and funding pathways that a device will be involved in, and of the 
decision-making processes involved in having a device accepted for reimbursement. Detailed coverage of 
reimbursement methods is beyond the scope of this chapter, but it is worth mentioning the growth in 
popularity of a formal method known as Diagnostic Related Groups (DRGs) that was introduced by the 
major US health insurer Medicare and now has variants in many countries of the EU, Japan and Australia. 
DRGs are a classification of hospital case types into groups expected to have similar hospital resource use, 
which code for a tariff that is calculated from a fixed base rate along with a weighting to adjust for 
hospital size and other factors. An important characteristic of the DRG method of reimbursement is that it 
is not based on the cost of a device alone, but rather by the entire cost of the hospital resources made up 
by the clinical interventions and services required for diagnosis and treatment of a disease, plus its 
possible complications or comorbidities. Tariffs are intended to be updated on a regular basis (at least 
every few years) so that they represent the true cost of the procedure. DRGs introduce a high degree of 
transparency into the reimbursement process, but their existence makes it all the more important to 
predict how a device will map to all of its intended uses with their various reimbursement codes and to 
use this knowledge to inform early decision-making.  
 
1.3 Health Technology and the role of HTA bodies 
 
Health Technology Assessment (HTA) aims to provide information to support healthcare decisions and 
policy making at local, national and international levels. The University of York’s Centre for Reviews and 
Dissemination (CRD) maintains an international database on behalf of the International Network of 
Agencies for Health Technology Assessment including a list of HTA bodies worldwide and records of 
ongoing projects being conducted.
5
 One example of an HTA body, the UK’s National Health Service (NHS) 
R&D division HTA programme, usefully defines health technology as follows:
6 
‘Health Technology is an internationally recognised term that covers any method used to promote health, 
prevent and treat disease and improve rehabilitation or long-term care. 'Technologies' in this context are 
not confined to new drugs or pieces of sophisticated equipment, but include procedures, settings of care 
and screening programmes.’  
Many HTA bodies are closely involved with reimbursement and the economics of healthcare delivery and 
they provide a speed of review that is faster when compared to the time required for rigorous surveys of 
clinical evidence, and in practice draw on existing surveys. The use of HTA in practice is typified by its 
fundamental role in the National Institute of Clinical Excellence (NICE) of England and Wales that was 
established in 1999 to appraise appropriate use of both new and existing health technologies, which 
include pharmaceuticals, medical devices, diagnostic techniques, clinical procedures and health 
promotion.
7
 Each NICE appraisal invites evidence from stakeholders including professionals, patient 
groups and manufacturers. Alongside this a Technology Assessment Report on clinical and cost-
effectiveness is commissioned from the national HTA Programme. NICE then uses the combined 
information from reports and stakeholders to inform its policy-making decisions. HTA gives government 
organizations like NICE considerable power over the introductions of new technologies and removal of 
existing ones if they become to be regarded as clinically ineffective or too costly. Therefore its growing 
prevalence and influence is something that healthcare technology developers should be aware of. The 
next section covers the equally important area of medical device regulation and standards. 
2. Medical devices and their regulation 
 
2.1 Definitions, principles and classes 
 
Medical devices are highly regulated. This is essential to ensure patient and practitioner safety, good 
performance and quality of manufacture in the pre-market stage, correct listing and advertising of the 
device that is being placed on the market, and fulfillment of post-market obligations such as detecting and 
alerting users of any problems and monitoring of a device’s clinical performance. The following sections 
are intended to give the reader an introduction to the essential pre-market regulatory processes and 
some of the post-market obligations with respect to the planning and realization of a device.  
 
2.1.1 Definitions 
 
The first step in the regulatory process towards marketing a medical technology product is knowing that it 
is a medical device. Definitions and nomenclatures for medical devices are not internationally agreed 
although this is being worked on by the Global Harmonization Task Force (GHTF), which was founded in 
the 1992 by the European Union (EU), United States (US), Canada, Australia and Japan.
8
 These efforts 
have been facilitated by the passing of EU-wide harmonization legislation, the US Federal Drug 
Administration (FDA) Modernization Act, and through substantial adoption of GHTF recommended 
models by the Therapeutic Goods Administration (TGA) in Australia, the Therapeutic Products Directorate 
(TPD) in Canada, and by Japan’s Ministry of Health, Labor, and Welfare (MHLW). Naming of devices is 
becoming standardized via ISO 15225 Nomenclature – Specification for a nomenclature system for medical 
devices for the purposes of regulatory data exchange, which is helping to facilitate international 
consensus on a Global Medical Device Nomenclature (GMDN) that is endorsed by the GHTF. The GHTF has 
proposed a harmonized definition for medical devices (document SG1/N029R11),
8
 but it is instructive to 
see the differences between the US and EU as they currently stand. Therefore, definitions for medical 
devices in the two regions will now be considered.  
The FDA, via its Center for Devices & Radiological Health, describes a medical device as:
9 
‘an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or 
related article, including a component part, or accessory which is: 
 recognized in the official National Formulary, or the United States Pharmacopoeia, or any 
supplement to them,  
 intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, 
treatment, or prevention of disease, in man or other animals, or  
 intended to affect the structure or any function of the body of man or other animals,  
and which does not achieve any of it's primary intended purposes through chemical action within or on the 
body of man or other animals and which is not dependent upon being metabolized for the achievement of 
any of its primary intended purposes.’  
Within the EU, medical devices are covered by three important pieces of legislation comprising of the 
Medical Devices Directive (MDD), the Active Implantable Medical Devices Directive (AIMDD) and the In 
Vitro Diagnostics Directive (IVDD). The AIMDD applies to all active devices and related accessories 
intended to be permanently implanted in humans, the IVDD applies to all devices and kits used away from 
the patient to make a diagnosis of patient medical conditions, and the MDD covers all other devices that 
are not in the two special categories. Non-device products on the other hand are covered by a directive 
known as the Community Code on Medicinal Products for Human use. 
The MDD (93/42/EEC) defines a medical device as:
10
  
‘any instrument, apparatus, appliance, material or other article, whether used alone or in combination, 
including the software necessary for its proper application, intended by the manufacturer to be used for 
human beings for the purposes of:  
 diagnosis, prevention, monitoring, treatment or alleviation of disease, 
 diagnosis, monitoring, treatment or alleviation of or compensation for an injury or handicap, 
 investigation, replacement or modification of the anatomy or of a physiological process, 
 control of conception, 
and which does not achieve its principal intended action in or on the human body by pharmacological, 
immunological or metabolic means, but which may be assisted in its function by such means.’ 
Part of the rationale behind the form of these definitions is to distinguish devices from pharmaceutical 
products. Although from a patient’s point of view, devices and drugs are complementary parts of 
managing their health, there are some important differences from HTA
7
 and other perspectives as shown 
in Table 1. Within MDD definitions an infusion pump that supplies a pharmaceutical is a device whereas a 
conventional pill capsule is not, and some drug-device combinations are also covered as devices. It is 
worth noting that some recent developments such as biologic coatings, tissue-engineered products and 
other drug-device combinations are further pushing at the borderline, so that clarifications to legislation 
have been and continue to be necessary.  
 
(INSERT TABLE 1 ABOUT HERE – find table after references) 
  
2.1.2 Essential principles 
 
In addition to definitions, the MDD provides Minimum Essential Requirements (Annex I) for the design and 
manufacture of medical devices to ensure the protection of the health and safety of patients, users and 
third parties, which makes safety a central principle in the legislation
11
. The requirements include 
(although this list is not exhaustive): 
 
 a general requirement for inherently safe design and construction, 
 safety and compatibility of materials, including medicines if acting as an ancillary device, 
 no adverse effect on characteristics or performance from normal use, transportation or storage, 
 elimination, minimization, protection against and informing of risk, ensuring residual risk is 
acceptable when weighed against benefit to the patient. Risks include those posed by: 
o substances leaking into or out of the device, 
o infection and microbial contamination, 
o tissues of animal origin, 
o ionizing radiation, 
o a device being connected to, or equipped with, an energy source (electrical, mechanical, 
thermal risks), 
o combination of devices with, and connection to, other systems, 
o environmental conditions, incl. interference with other devices, and, 
o aging of a device. 
 ergonomic design, 
 sufficient accuracy, if a measuring device, and, 
 adequate product marking and user instructions. 
  
The MDD essential requirements have for the most part been adopted by the GHTF Essential Principles of 
Safety & Performance of Medical Devices (SG1-N020R5)
8
 and are therefore likely to be the basis for future 
international consensus. 
 
2.1.3 Device Classes 
 
Once you know your product is a medical device, the next important step is to know its class since this 
determines the route to conformity. Again, although not universally agreed by regulators, there is a 
degree of harmonization whereby medical devices are classified into three or four classes according to 
level of risk, use and degree of invasiveness. The higher the risk, the higher the class number. Devices may 
also be classified during development e.g. the  FDA classifies investigational devices in two classes: 
Significant Risk (SR) or Non-Significant Risk (NSR). 
Currently, however, there are alternative approaches to actually determining the device class for a new 
device. In the EU this is done by applying a set of 18 rules (as specified in MDD Annex IX) with additional 
special rules for Active Implantable Medical devices and In Vitro Diagnostic devices, whereas in the US 
classification is carried out by government expert panels under Title 21 of the Code of Federal Regulations 
(CFR) whereby a device is generally assumed to be high risk unless it can be shown otherwise. The panel 
method can introduce uncertainty into the process, which can be especially worrying if the device is 
bordering on high risk since this increases the cost of obtaining conformity. On the other hand, a rule-
based type method can be difficult to apply although for the MDD there are some useful additional 
guideline documents.
12
 Table 2 shows the types of devices in the various classes which result from the 
MDD rules. Non-active and accessory equipment is classified along with the active devices that are of 
most interest to pervasive healthcare designers. Further discussion about classification in the EU and US 
and global trends can be found in Davey et al.
13 
 (INSERT TABLE 2 ABOUT HERE – find table after references) 
  
2.2 Regulatory matters 
 
2.2.1 Conformity 
Conformity is the successful outcome of the compulsory regulatory processes by which a medical device 
will be accepted for marketing in a particular region.  In the EU, conformity is shown by obtaining CE 
marking which means the device is certified to have met regulatory requirements. This includes 
adherence to the essential principles of the directives as assessed by an accredited third party (Notified 
Body) in the case of Class II/III devices or via self-assessment in the case of a Class I low risk device 
(provided the company is registered as meeting a quality systems management standard). In the UK, 
notified bodies are audited by the Medicines and Healthcare products Regulatory Agency (MHRA) of the 
Department of Health. In the US, conformity is shown by obtaining FDA approval from the government by 
going through one of two processes. Premarket approval (PMA) involves demonstration of reasonable 
safety and effectiveness which is required for a high-risk or new kind of device. A less-stringent Premarket 
Notification 510(k) process is allowed for devices that are substantially equivalent (SE) to a device already 
on the market, known as a predicate device. According to the FDA:
9 
 
‘a device is deemed to be SE if, in comparison to a predicate device it: has the same intended use as the 
predicate device; and has the same technological characteristics as the predicate device; or has different 
technological characteristics, that do not raise new questions of safety and effectiveness, and the sponsor 
demonstrates that the device is as safe and effective as the legally marketed device. A claim of substantial 
equivalence does not mean the new and predicate devices must be identical. Substantial equivalence is 
established with respect to intended use, design, energy used or delivered, materials, performance, safety, 
effectiveness, labeling, biocompatibility, standards, and other applicable characteristics.’
 
Some 1,700 devices are already classified by the FDA so it is essential for the innovator of a device to 
check for substantial equivalence in determining the likely route to compliance for marketing it in the US. 
An illustrative example of SE devices are 3D navigation systems for computer-aided orthopedic surgery 
which are predicated to stereotaxic equipment that was originally developed for neurosurgery. Because 
of this several manufacturers have obtained approval via the 510(k) route. In contrast, companies found it 
difficult to obtain FDA approval for robotic orthopedic surgery systems due in part to the lack of a suitable 
predicate device, which therefore necessitated the PMA route.  
2.2.2 Standards 
 
Adherence to product standards is a vital component of the regulatory process, and although pre-market 
standards vary in format in different regions, they universally apply to three main areas according to the 
World Health Organization:
14 
 Device attributes: Product safety and performance 
 Manufacturing: Quality system  
 Labeling: Description, and instructions for use 
There are a large number of international and regional standards relating to medical devices
15
. For an 
overview of such standards, see ISO TR16142 Medical devices - Guidance on the selection of standards in 
support of recognized essential principles of safety and performance of medical devices. There is also a 
fairly recent comprehensive reference by Fries.
16
 Device attributes standards are very much related to the 
essence of the essential requirements as previously described for the MDD. Data standards, since they are 
very important to pervasive systems, will be considered later on in this section. Standards for clinical 
studies, although linked to safety and performance, will also be mentioned in a separate section. 
Manufacturing standards are for the most part covered by quality assurance (QA) systems that are 
required for the production and testing of all classes of device. In the EU this is now covered by the 
medical device standard ISO 13845. In the US, a company must follow Good Manufacturing 
Practice/Quality Systems (GMP/QS) standards. These standards require design controls and 
documentation for the manufacturing process. Labeling standards contribute to safe use and tracking of 
products.  
Rather than go into specific details, it is perhaps more useful in a changing regulatory environment to 
examine trends in the evolution of standards in recent years, as follows (with relevant examples): 
 Regulations are subsuming many voluntary standards, which is deemed useful because it is 
easier to change a standard than a regulation and this also aids governments in creating 
regulations. An exception is the area of environment protection which is becoming more 
regulated (see below). 
 Standards are becoming more sector specific. For example, the general ISO 9001 quality standard 
is now for the most part incorporated into ISO 13485 Medical devices - Quality management 
systems - Requirements for regulatory purposes. ISO 90003  Software engineering - Guidelines for 
the application of ISO 9001:2000 to computer software and IEC 61508 Functional Safety of 
Electrical / Electronic / Programmable Electronic Safety-related Systems are likely to be 
supplemented by IEC 62304 Medical device software - software life-cycle processes. 
 Standards are coming more internationally recognized e.g. updated US and Japanese GMP 
standards are being based on the new ISO 13485:2003. This is intended to assist in facilitating 
global trade and access to new technologies. The GHTF has also proposed a documentation 
system to harmonize collation of all the material needed for pre-market approval applications, 
known as Summary Technical Document (STED), which is currently being piloted and evaluated 
by its members. 
 Standards are becoming less prescriptive in terms of tools and methods, but instead are taking 
on essential principles (e.g. for performance) and a risk management philosophy that requires 
the manufacturer to actively take the responsibility for implementing and continually reviewing 
its processes to analyze, identify and control risk. As an example, the forthcoming 3rd edition of 
IEC 60101 Medical Electrical Equipment will require adherence to ISO 14971 Medical devices - 
application of risk management in medical devices.  
 Usability engineering is becoming less of a guideline and more of a requirement. This is related to 
risk management and arose from the need to understand and mitigate potential misuse. In 
particular usability will be fully incorporated into the 3rd edition of IEC 60101 and the scope of 
use will also change from ‘under medical supervision’ to ‘all use’. This is alongside recognition of 
the need to have tight controls on home use. 
 Sustainability and environmental protection are becoming more regulated, building on voluntary 
environmental management standards such as ISO 14001. Example include the EU’s Waste from 
Electrical & Electronic Equipment (WEEE) and Restriction of Certain Hazardous Substances (RoHS) 
directives and Integrated Product Policy (IPP), where greater responsibility is placed on 
manufacturers regarding the disposal of devices, necessitating ‘cradle-to-grave’ engineering. The 
Eco-design requirements for energy-using products (EuP) directive is intended to make electrical 
devices more environmentally friendly. Japan has also passed a set of environmental laws 
including Home Appliances Recycling Law (HARL), Law for the Effective Utilization of Resources 
(LPEUR) and Green Purchasing Law (GPL).  
 Recognition is rising regarding the need to ensure safety of refurbished and denoted equipment 
as well as the reprocessing of devices labeled for single-use. This includes equipment intended 
for reuse in developed countries, and, for trade and donation of equipment to developing 
countries, some of whom have previously had bad experiences with used equipment.
14
 
 
2.2.3 Post-market surveillance, vigilance and adverse incident reporting 
 
Once a device is on the market and is being used by practitioners and patients, it is important that its 
safety and performance continue to be assessed. Devices can be used and misused in many different and 
unforeseen ways (perhaps as a result of inadequate labeling and user instructions) and, in spite of pre-
market efforts, can fail in actual use or otherwise incur complaints from customers. Changes in clinical 
practice may also impact on actual use of a device, while advances in state-of-the-art technology can 
demand changes to a design. This is quite apart from the processes of HTA which as we have seen are 
used to assess and reassess clinical effectiveness and cost effectiveness for policy-making purposes.  
The two main methods by which post-market assessment is implemented are post-market surveillance 
(PMS) studies by the manufacturer and by gathering and disseminating information through adverse-
incident reporting networks. In Europe a related term vigilance is used to denote the responsibility of the 
manufacturer to track and report on problems arising with a device. 
Post-market activities are for the most part covered by the requirements of standards and regulations. 
For example, under the US Code of Federal Regulations (CFR) the FDA may impose post-market evaluation 
and periodic reporting on a manufacturer as part of the PMA approval of a device (21 CFR Part 814) and 
can also order subsequent postmarket surveillance for any Class II and III device where there is a serious 
risk to health from device failure, as well as for long-term implants or life-sustaining devices (21 CFR Part 
822).  The EU MDD requires the manufacturer to have systematic procedure to deal with post-market 
experience of a device. Additionally the relevant body (Competent Authority) must be informed of any 
deficiencies that resulted (or could have resulted) in death or serious deterioration of health and/or of the 
technical or medical reason for the recall of a device. There are also a variety of methods recommended 
for conducting PMS such as active supervision, customer surveys, inquiries of users and patients, 
literature reviews, and post-market clinical follow-up (PMCF). PMCF is recommended for capturing 
infrequent complications and long-term performance issues that would not be detected in the pre-market 
phase, as outlined in guidance MEDDEV 2.12/2.
12
  
 
2.2.4 Data issues 
 
A key feature of pervasive healthcare is the interaction of devices with information and communication 
technology (ICT) systems. This convergence of technologies is becoming manifest by widespread use of 
commercial off-the-shelf (COTS) hardware and software such as the personal computer, and the use of 
standards-based communications such as wired and wireless Ethernet as outlined by Cohen.
17
 As Cohen 
points out, COTS and data communication technologies can together facilitate automatic data collection, 
analysis, reporting, dynamic reconfiguration and remote software upgrading for medical devices. The 
move to electronic patient records is likely to go hand in hand with increased demand for devices with a 
computer interface. 
There are a number of standards and initiatives in the area of data communications that are specific to 
medical technologies. One such industry standard is Digital Imaging and Communication in Medicine 
(DICOM) which originates from the need to transfer medical images from computerized tomography (CT) 
and magnetic resonance imaging (MRI) scanners. The other well-established industry standard is High 
Level 7 (HL7) designed for hospital administrative data exchange. IEEE 1073/ISO 11073 Health informatics 
– Point-of-care medical device communication is an international standard that currently at the draft 
stage. A recent initiative emanating from the US is Integrating the Hospital Environment (IHE) which aims 
to bring together usage of DICOM, HL7 and internet protocols in healthcare systems within a set of  
Technical Frameworks for various healthcare domains e.g. IT Infrastructure, Cardiology, Laboratory, 
Radiology.
18
 Furthermore, the US National Academies have recently published an in-depth report 
highlighting the need for partnership between engineering and medicine in order to apply the best 
systems engineering approach to healthcare delivery that is, ‘safe, effective, timely, patient-centered, 
efficient and equitable’.
19 
Data security is an issue that is receiving particular attention with the introduction of electronic patient 
records. In the US, the Health Insurance Portability and Accountability Act (HIPAA) requires, as of 21 April 
2005, that healthcare providers adopt a security procedure to ensure the integrity, availability and 
confidentiality of information maintained and transmitted by medical devices.
20
 From a service provision 
perspective, Grimes outlines the need to shift from management of discrete devices towards an overall 
policy of safeguarding information, and lists a range of device and system requirements that might be 
used to mitigate security threats.
21
 These threats include hardware failures or errors, user misuse or 
abuse of a device, erroneous data entry, malicious assault, unauthorized data access and/or modification, 
and environmental effects such as electromagnetic interference (EMI) or interruption of utilities such as 
power. These and other issues related to data handling and protection must therefore feed into the 
design process for pervasive healthcare devices and systems. 
 
2.3 Clinical studies  
 
A key aspect within the pre-market processes for proving and approving medical devices is the gathering 
and use of data concerning its clinical efficacy and safety. For certain classes of device, clinical approval 
resulting from the outcomes of testing on human subjects will be mandatory for its market certification. 
This might involve actual clinical studies or the compilation and critical analysis of existing evidence from 
the literature and other sources concerning similar devices.
22
 Even for low risk devices, clinical data may 
be important for proving the need and benefits of a product to users and payers. 
Pre-market clinical studies typically take place after detailed design of the device is completed. Data 
which is intended to be used for predicting clinical effectiveness on living humans, especially for invasive 
devices, is also commonly obtained in the development stage from animal experiments, human cadavers 
and tissue. Pre-clinical information may also be gained from systematic consultation of individuals or 
groups of healthcare professionals and patients, as well as from modeling exercises. 
If the conducting of a clinical trial is necessary due to insufficient existing evidence, the manufacturer is 
required to follow procedures in applying for permission to do so, and for the running of the trial. The 
processes for doing this are regulated by the same bodies as in section 2.2.1, and various standards are 
applicable. Devices at this stage are legislated for their clinical study in the US through the Investigative 
Device Exemption (IDE) regulation (21 CFR 812) and in the EU through clinical investigation requirements 
in the MDD, with guidance issued via MEDDEV 2.7 Clinical investigation, clinical evaluation: Guide for 
manufacturers and notified bodies.
12
 International standard ISO 14155 Clinical Investigation of Medical 
Devices for Human Subjects covers recognized practices for conducting trials. In the US, and elsewhere, 
clinical and laboratory practices are governed by requirements known as Good Clinical Practices (GCP) 
and Good Laboratory Practices (GLP). 
Although the details of clinical trials methods and approval processes are outside the scope of this 
chapter, the remainder of the section will concentrate on ethical approval aspects since this is also 
relevant to pre-clinical studies that device designers may also be involved in. Some developments in post-
market clinical trial design, that are intended to be more suitable for medical device evaluation from an 
HTA perspective, will also be introduced. 
 
2.3.1 Ethics 
 
Before conducting human clinical studies, and indeed even before systematic pre-clinical consultations 
with professional and patients (or healthy volunteers), it is a normal requirement to have obtained ethical 
approval from the institutions involved. This typically involves interaction with healthcare service 
providers. By way of an example, within the UK’s National Health Service there are local research ethics 
committees (LRECs) who make decisions about single-centre studies and multi-site research ethics 
committess (MRECs) for streamlining studies that span multiple sites.
23
 A developer must apply to obtain 
the necessary approval from these committees by supplying the detailed plan (protocol) of the 
experiment to be carried out and, preferably, advance permission from all of the participating centers. 
LRECs are guided to consider the following general criteria and any other criteria specific to the 
experiment:
24 
1. Has the scientific merit of the proposal been properly assessed? 
2. How will the health of the research subjects be affected? 
3. Are there possible hazards and, if so, adequate facilities to deal with them? 
4. What degree of discomfort or distress is foreseen? 
5. Is the investigation adequately supervised and is the supervisor responsible for the project 
adequately qualified and experienced? 
6. What monetary or other inducements are being offered to the NHS body, doctors, researchers, 
subjects or anyone else involved? 
7. Are there proper procedures for obtaining consent from the subjects or where necessary their 
parents or guardians? 
8. Has an appropriate information sheet for the subjects been prepared? 
An illustration of ethics committee workings, for FDA-supported research can be found via the US Office 
of Human Research Protections.
25
 This explains the role of Institutional Review Boards (IRBs), the 
equivalent of RECs in the US.  
Research ethics has a considerable impact on the methods by which evidence on the efficacy of a medical 
device can be obtained. Protection of human subjects and patients is paramount, and stringent legislation 
covering all human subjects is accompanied by special rules to protect specific groups, for example 
children, prisoners and cognitive disabled persons. Furthermore, in recent years special research ethics 
rules and guidelines have been devised for experiments involving genetics, human and animal tissues and 
organs. These guidelines may become more relevant to device designers as the number of drug-device 
combination products proliferates. Animal experimentation is receiving renewed ethical consideration in 
many countries as a result of greater attention to animal welfare issues, the question of efficacy of animal 
models and cost, and especially due to a more concerted adoption of the principles of the 3R’s – 
replacement, reduction and refinement of animal use. In Australia, this has become most sophisticated by 
means of the Animal Ethics Committees (AECs) that have been introduced into animal welfare legislation 
through a revised Australian code of practice for the care and use of animals for scientific purposes.
26
  The 
AECs act as decision-making bodies a similar manner to RECs. In the UK, a government-funded Centre for 
the 3R’s has recently been established whose stated aim is the ultimate replacement of animal use.
27
 
Further information about research ethics for both humans and animals can be obtained via the Online 
Ethics Center website.
28 
In addition to RECs there are a number of other types of ethics committees. In the UK for example, Clinical 
Ethics Committees (CECs) provide advice and support on ethical issues arising from clinical practice and 
patient care within health care organizations.
29
 Although these committees are not decision-making 
bodies like RECs, they may influence aspects of healthcare such as hospital procedures and equity of 
access, which may be quite relevant to a technology developer. Finally, ethics in business is experiencing a 
growth in concern within the medical device sector, which is relevant to the collaboration of companies 
with healthcare professionals (HCPs). For example, the US medical devices trade association AdvaMed has 
recently adopted a voluntary Code of Ethics to facilitate ethical interactions with HCPs who may 
‘purchase, lease, recommend, use, arrange for the purchase or lease of, or prescribe Members’ medical 
technology products in the U.S.’.
30 
 
2.3.2 Advances in clinical trials for devices 
 
The ‘gold standard’ for clinical trials is the Randomized Controlled Trial (RCT) that was developed for 
evaluating drug treatments but is now used for the full range of clinical procedures. However, there are 
some problems associated with RCTs for medical devices because of the differences between devices and 
drugs as shown previously in Table 1. In a useful illustration of this, Lilford et al. have outlined some of the 
issues involved in surgical trials, which often involve devices, showing how application of the RCT can be 
problematic.
31
 These issues include ethics of intervention versus non-intervention, the problem of 
blinding of participants (surgeons, patients and hospital staff), surgeon- and technique-related variables, 
timing of trials, patient preferences, entry criteria, appropriate outcome measures, and a number of 
statistical considerations. As a result, less powerful clinical studies, such as cohort studies and case-
studies, are quite prevalent in the literature for medical devices. However, the value of studies lower 
down in the hierarchy of evidence can be difficult to assess from the HTA perspective. Lilford et al. argue 
strongly for randomization and in a separate paper propose tracker trials for comparing fast-changing 
technologies like devices.
32
 Tracker trials include the set of contemporary examples of treatments 
employed by clinicians but allow for the addition of new devices and treatments into the study as the trial 
progresses. This is to help ensure early adoption if a new procedure is found to be superior, as well as for 
removal of a procedure if it shown to be performing poorly or if it has been superseded by technological 
developments. These are still randomized trials, but they do not have preset and rigid protocols and are 
ongoing studies rather than the one-off event that characterizes an RCT. New developments of this kind 
may become influential in the future of medical device assessments. 
3. Routes for medical devices innovation 
 
Having covered some of the nuts and bolts of medical device development and their accompanying 
regulations and standards in the previous two sections, we are now in a position to look at the overall 
innovation process.  
 
3.1 New product development processes 
 
New Product Development (NPD) methods typically break the innovation process down into a series of 
stages with associated decision-making, called stage-gate systems.
33
 Such processes are aimed at helping 
to reduce development time and improving quality through standardization of practice and subsequent 
capture of best practice. Rochford and Rudelius have studied medical devices in this context, comparing 
‘new-to-the-world’ products and product modifications using a 12-stage process.
34 
Members of the author’s Multidisciplinary Assessment of Technology Centre for Healthcare (MATCH) 
have recently completed a consultation with our industrial partners that has resulted in a simplified 4-
stage generic process for medical devices, giving a snap-shot of the current approach to product 
development in the industry
35,36
. This process is summarized in Figure 1. Much of the progression of 
stages will be familiar to project managers and product developers. However, there are some points for 
special note. Firstly, there will be more stages in practice. The 4-stage model is intended to be a high-level 
representation of the decision-making steps involved. Secondly, as a result of the regulatory processes 
that must be undertaken, the first three stages involve a great deal of planning before detailed product 
design can be attempted, after which strict design controls must be in place to track and document all 
modifications. This is quite typical of safety-critical systems. These controls and the validation processes 
that close the iterative loops during Stage 3 have received attention by others in terms of guidance to the 
medical device industry (e.g. the Cambridge Engineering Design Centre’s Design for Validation 
approach).
37 
 
(INSERT FIGURE 1 ABOUT HERE – find figure after references) 
 
A notable omission in documented current practice is specific planning for HTA and reimbursement as 
mentioned earlier in the chapter. This is being addressed in MATCH by the promotion of health economics 
modeling
38
 which would benefit from its earliest adoption in Stage 1, with subsequent refinement at 
other stages, such as during clinical trials.
39
 The other main omissions are the environmental and 
sustainability strategies that will have to be put in place as the newer regulations are introduced. These 
will require the industry to go beyond dealing with retirement of obsolete devices and towards advance 
planning for disposal at the point when detailed requirements are drawn up and design decisions 
involving choices of materials and energy use are made. Sourcing, procurement, reporting, servicing and 
repair are all areas that will be affected by such legislation.
40 
A further development areas is the approach to stakeholder requirements, especially in the area of user 
needs capture to ensure devices are fit-for-purpose. As we have seen this is another area that is moving 
from guidance towards regulation, and will benefit from review throughout the lifecycle, suggesting the 
introduction of more formal human factors methods into the concept design phase of Stage 2 and specific 
planning for usability testing in Stage 3.  
 
3.2 Special considerations for pervasive medical device development 
 
For devices involving data, which are inherent to pervasive computing in healthcare, the communication 
and security issues mentioned earlier will need specific planning for since they will impact on design 
choices, user testing and post-market surveillance. Since regulations and standards are in continual 
development it will be most beneficial for pervasive healthcare designers to engage with the bodies 
concerned with these. Interaction with patient groups will help provide insights into public concerns 
about protection of personal records. 
 
Since many pervasive healthcare devices are likely to be used in the home, this raises obvious concerns in 
the area of maintenance and disposal/recycling as mentioned above. Comparison with the experiences of 
deploying equipment for disabled users by healthcare providers would be useful in this respect. As well as 
those supplied by professionals, many pervasive healthcare devices are likely to be purchased over-the-
counter, and this will raise further issues such as ensuring adequate training. 
Finally, the best combined methods to use for user needs capture of pervasive healthcare devices in 
conjunction with the ICT systems they interact with is still an open question that would benefit from 
further research.
41 
4. Conclusions 
 
The environment of the pervasive healthcare innovator is a multidisciplinary one, bringing together the 
roles of the clinical designer/engineer and ICT specialist. It is hoped that this chapter has provided an 
insight into the processes of healthcare technology development.  On the device side especially, there is a 
need for understanding the regulatory processes within the product life-cycle plus other aspects which 
might normally be outside a designers remit, such as reimbursement and HTA processes. Bringing this 
knowledge into the design process should help to improve decision-making in medical device innovation. 
 
In a large medical devices organization, there will most likely be expert individuals and departments in 
some of the specific areas outlined in this chapter such as clinical trials and regulations so it will not be 
necessary for designers to have detailed knowledge of these. Of course, this is the benefit of a 
multidisciplinary team. For a small company or university research group, however, it is more likely that 
individuals will need to become multidisciplinary to some extent.  
Medical device regulations and standards are presently going through great changes and the web has 
become an important medium for accessing the latest information and advice, highlighted by the large 
number of online references in this chapter. Official sources of information on regulations and extensive 
guidance include the Medical Devices Directives
10
 and MEDDEV
12
 in the European Union, Device Advice
9
 
in the USA, and via the websites of the other members of the Global Harmonization Task Force
8
. Industry 
supporting websites and magazines such as Medical Devicelink
42
, Medical Device Technology
43
 and 
publications of professional bodies such as the IEEE Engineering in Medicine and Biology Society
44
, are 
further useful sources of advice and information for medical technology developers. 
Pervasive computing is an exciting field that should contribute in addressing and solving many of issues 
involved in developing new healthcare technologies and bringing them to patients.   
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Tables and figures 
 
Table 1 Comparison of medical devices and drugs 
 Devices Drug 
Principal Action Other than pharmacological, immunological or metabolic 
means  
Often mechanical, electrical or materials engineering 
based  
Pharmacological, immunological or metabolic 
means  
Chemical based  
Product Life Cycle Constantly evolving, incremental modification 
Often short life cycle 
Unchanging compound 
Long life cycle 
Clinical 
Evaluation 
Lower requirement for clinical investigation (class 
dependent) 
Difficult to blind (to find a placebo), crossover common 
Difficult to stabilize for conventional RCT 
Multiple end users 
More formalized evaluation and extensive clinical 
investigation 
Easy to blind with a placebo, crossover rare 
Use conventional Randomized Controlled Trials 
Usually one end user 
Use issues Results vary with operator skill 
Wide range of over-the-counter availability 
Often require intensive training to use 
Complications decrease with use 
Results unrelated to physician skill 
Majority prescribed 
Low training requirement 
Complications increase with use 
Diversity A few large companies and many small companies (SMEs) Mainly large multinational companies  
Costs Varying overheads with slow return 
High distribution cost 
High maintenance and disposal/recycling costs 
High overheads, but quicker return 
Low distribution cost 
Low disposal costs 
 
 
Table 2. Examples of product classifications arising from MDD rules, collated from guidance document 
MEDDEV 2.4/1 – rev. 8 PART 2: July 2001
12
  
Device Class Examples 
I, low risk Active diagnostic devices intended to illuminate or view the patient's body in the visible spectrum e.g. examination lights, 
surgical microscopes. Dental curing lights. 
Active diagnostic devices intended for thermography; devices for recording, processing or viewing of diagnostic images. 
Devices intended in general for external patient support e.g. hospital beds, patient hoists, walking aids, wheelchairs, 
stretchers, dental patient chairs. 
Incontinence pads, non-sterile dressings, plaster of Paris, corrective glasses, non-invasive electrodes (for EEG or ECG), image 
intensifying screens, cups and spoons, syringes without needles, dentistry mirrors, gloves, reusable scalpels, saw blades, 
tubing for transient use. 
IIa, medium 
risk 
Active therapeutic devices intended to administer or exchange energy, unless doing so in potentially hazardous way: 
Electrical, magnetic, electromagnetic - Muscle stimulators and external bone growth stimulators, TENS devices and eye, 
electromagnets, electrical acupuncture; Thermal - Cryosurgery equipment, heat exchangers, except the types described 
below; Mechanical - Powered dermatomes, powered drills and dental hand pieces; Light - Phototherapy for skin treatment 
and for neonatal care; Sound - Hearing aids; Ultrasound: Equipment for physiotherapy. 
Many active devices intended for diagnosis e.g. imaging devices (MRI, evoked response, diagnostic ultrasound, Gamma 
cameras, PET, SPECT), ECG, EEG, electronic thermometers, stethoscopes & blood pressure measuring equipment. Also, X-ray 
films, photostimulable phosphor plates. 
  
Active devices intended to administer and/or remove medicines, body liquids or other substances to or from the body, 
unless potentially hazardous e.g. Suction equipment, feeding pumps, Jet injectors for vaccination, non-dose critical nebulae’s 
 
Channels for active drug delivery and blood, syringes for infusion pumps, devices for temporary storage of transplant organs 
or long-term storage of bodily materials, filtering machines & centrifuges (mechanical separation). Most tubing for short 
term use e.g. urinary catheters, tracheal tubes, stents. Wound dressings managing the micro-environment e.g. polymer film.  
Dental prostheses.  
Many surgically invasive devices intended for transient use e.g. needles used for suturing, needles of syringes, single use 
scalpels/blades, drill bits connected to active devices, trial implants. 
Devices intended specifically to be used for disinfecting medical devices, except contact lens solution. 
IIb, elevated Active therapeutic devices intended to administer or exchange energy, doing so in potentially hazardous way: Kinetic energy 
- lung ventilators; Thermal energy - incubators, warming blankets, blood warmers, heat exchangers; Electrical energy - high-
frequency electrosurgical generators, electrocautery equipment and electrodes, external pacemakers, external defibrillators, 
electroconvulsive therapy equipment; Coherent light - surgical lasers; Ultrasound - lithotriptors, surgical ultrasound devices; 
Ionizing radiation - radioactive sources for afterloading therapy, therapeutic cyclotrons, linear accelerators, therapeutic X-ray 
sources. Also, active devices intended to control and monitor the performance of active therapeutical devices in Class IIb e.g. 
external feedback systems. Also, diagnostic X-ray sources. 
Intensive care monitoring and alarm devices (for e.g. blood pressure, temperature, oxygen saturation), biological sensors, 
blood gas analyzers used in open heart surgery, cardioscopes and apnea monitors, including apnea monitors in home care. 
Active devices intended to administer and/or remove medicines, body liquids or other substances to or from the body, 
unless potentially hazardous - Infusion pumps, ventilators, anesthesia machines, anesthetic vaporizers, dialysis equipment, 
blood pumps for heart-lung machines, hyperbaric chambers, pressure regulators for medical gases, medical gas mixers, 
moisture exchangers in breathing circuits if used on unconscious or non-spontaneously breathing patients, dose-critical 
nebulae’s. 
Catheters incorporating sealed radioisotopes, excluding the central circulatory system (CCS), tubing for long term use e.g. 
urethral stents, Wound dressings with secondary healing properties.  
Many implantable devices e.g. prosthetic joint replacements, non-implantable devices used for contraception or the 
prevention of the transmission of sexually transmitted diseases e.g. condoms, diaphragms. Dose-critical medicine applicators 
e.g. insulin pens, surgically invasive adhesives, contact lens solutions. 
III, high risk Cardiovascular catheters e.g. angioplasty balloon catheters incl. guidewires, dedicated disposable cardiovascular surgical 
instruments. Catheters incorporating sealed radioisotopes for central circulatory system (CCS). 
Implantable devices to be used in direct contact with the heart, the CCS or the central nervous system (CNS) e.g. heart 
valves, spinal stents, CNS electrodes. Implantable contraceptives e.g. intrauterine devices. Bioactive implantable devices e.g. 
absorbable sutures and biological adhesives. 
Rechargeable non-active drug delivery systems. 
All devices incorporating a medicinal product as an integral part with an action ancillary to that of the devices: Antibiotic 
bone cements, condoms with spermicide, heparin coated catheters, endodontic materials with antibiotics, some ophthalmic 
irrigation solutions,  dressings incorporating an antimicrobial agent to provide ancillary action on the wound. 
 
 
 
Figure 1. A four-stage innovation process for medical device development (Adapted from Dixon et al.
35
 
and Eatock et al.
36
 With permission.) 
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